GameStop is entering the final stretch before its September 1 earnings report with the same defensive posture that has characterised the past two weeks — but the borrow market has tightened meaningfully since last week's note, adding a new dimension to an already charged setup.
The options signal is now the defining feature of this pre-earnings window. Tuesday's put/call ratio of 0.547 is 4.3 standard deviations above the 20-day mean of 0.304. That is not noise. For the prior six weeks, the PCR never closed above 0.310. It has now broken sharply higher twice in eight trading days — the August 11–12 episode and now this one — each time collapsing back to baseline within a session, then reloading. The 52-week high is 0.806; the current reading trails only that peak in the available data. Options traders are pricing downside protection aggressively, and the pattern of rapid spikes followed by brief reversions is itself a signal: this is not a single-day hedging quirk but a recurring, concentrated demand for puts as the earnings date closes in.
The borrow market has shifted this week in a way that deserves attention. Availability has tightened to 59%, down from 83% just eight days ago on August 11 — the tightest level in roughly a month. That compares with readings above 100% through most of late July, when there were more shares available to borrow than already borrowed. The lending pool has not dried up — the 52-week low availability was 1.4%, so there is still meaningful headroom — but the directional move is clear and accelerating. Cost to borrow, at 0.64%, remains low in absolute terms and has actually eased modestly on the week. Short interest itself is a large position at roughly 13.9% of the free float, little changed from last week's 62.1 million shares, and up about 11% over the past month. The short book is not growing aggressively, but it is not covering either. Overall, the borrow picture is tightening without yet reaching levels that would stress existing short positions.
The Street has essentially one voice on this stock, and it is skeptical. Wedbush's Michael Pachter has maintained an Underperform rating with a $13.50 target — but that view was last refreshed in June 2025, more than a year ago, and should be read as directional context rather than a current opinion. The $13.50 target is materially below Tuesday's close of $17.95. Valuation multiples are difficult to interpret cleanly given the company's negative earnings; what is clear is that at roughly $18 the stock trades well above where its fundamental story would place it, which is precisely why the short book remains so large. The ORTEX short score of 80.2 ranks in the 98th percentile of the universe — a reading that reflects both the elevated SI % of free float and the tightening borrow conditions. Institutional holders are broadly passive: BlackRock, Vanguard, and State Street collectively hold a significant position, but the largest single holder remains CEO Ryan Cohen at 8.5% of shares.
Earnings history gives some texture for what the September 1 print might look like. The last four post-earnings sessions produced moves of –4.7%, +0.7%, +3.8%, and –1.1% on day one — a range of nearly 8.5 percentage points, with no directional consistency. The five-day windows are similarly scattered. The stock does not have a reliable pattern of post-earnings drift in either direction, which makes the current options hedging harder to read as a directional bet and more likely to represent uncertainty about the magnitude of the move rather than a conviction call on the direction.
The question heading into September 1 is whether the PCR spike holds for a third time, or collapses again as it did on August 14 — and whether the borrow market continues tightening toward the kind of availability levels that could introduce covering pressure into whatever price action the earnings print generates.
See the live data behind this article on ORTEX.
Open GME on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
